Vera Therapeutics recently appointed Matt Skelton as Chief Commercial Officer, effective January 28, 2026, elevating him from his prior role as Executive Vice President, Commercial to lead ...

From revolutionary tech founders to self-made business icons, this article highlights the Top 10 Trailblazing Entrepreneurs ...

Dr. Stacy Lindborg is president and CEO of IMUNON, a clinical-stage company in phase 3 development with a lead DNA-mediated immunotherapy for advanced ovarian cancer. Dr. Lindborg has worked in the ...

ARBLI ™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. ARBLI ™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, ...

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the sale of its immuno-oncology related assets, consisting ...

Adyen, the global financial technology platform of choice for leading businesses, today announced that it has launched Fresha Capital, in partnership with Fresha, the world's leading marketplace ...

What if ultrasound imaging is no longer confined to hospitals? Patients with chronic conditions, such as hypertension and heart failure, could be ...

Beauty buffs can save nearly £100 on this best-selling face sculpting device that has shoppers raving they 'see a difference ...

On January 27, 2026, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) issued a Special Advisory Bulletin ...

Cancer drugs among nearly 400 medicines at risk of shortage in UK - Exclusive: Drugs to treat stroke and schizophrenia patients could be hit if suppliers no longer see them as commercially viable ...